Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares), primarily engaged in the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to the parent company was 554 million yuan, a decrease of 29.04% year-on-year [7]. - As of September 30, 2025, the company had a total of 27,000 shareholders, an increase of 2.60% from the previous period [7]. Market Activity - On November 27, the company's stock price fell by 1.43%, with a trading volume of 35.8725 million yuan and a turnover rate of 0.24%, resulting in a total market capitalization of 17.153 billion yuan [1]. - The company has seen a net outflow of 2.5375 million yuan from major funds today, with a ranking of 79 out of 159 in its industry [4][5]. Dividend Information - Since its A-share listing, the company has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its growth in overseas revenue and the impact of currency depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business segments include: - Formulations: 63.06% - CDMO: 18.59% - Heparin sodium and low molecular weight heparin raw materials: 16.05% - Others: 2.30% [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the Renminbi [3]. Market Activity - On November 26, the stock price of Hepalink increased by 0.51%, with a trading volume of 36.7143 million yuan and a turnover rate of 0.25%, leading to a total market capitalization of 17.402 billion yuan [1]. - The stock has seen a net outflow of 223,600 yuan from major funds today, with a ranking of 74 out of 159 in its industry [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.0093 million shares, an increase of 691,700 shares compared to the previous period [9]. Dividend Information - Since its A-share listing, Hepalink has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Company Overview - Haiprui is headquartered in Shenzhen, China, and was listed on May 6, 2010. Its main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The revenue composition of Haiprui is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounts for 93.04%, benefiting from the depreciation of the RMB [3]. - Haiprui has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 25, Haiprui's stock rose by 0.77%, with a trading volume of 37.2831 million yuan and a turnover rate of 0.25%, bringing the total market capitalization to 17.314 billion yuan [1]. - The stock has seen a net outflow of 1.3632 million yuan from major investors today, with a ranking of 113 out of 159 in the industry [4]. Technical Analysis - The average trading cost of Haiprui's shares is 11.59 yuan, with the stock price approaching a resistance level of 11.81 yuan, indicating potential for a price correction if it fails to break through this level [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 深圳市海普瑞药业集团股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第十八次会议（以下简称"会 议"）通知及议案于2025年11月17日以电子邮件的形式发出，会议于2025年11月24日下午14:00在深圳市 南山区松坪山朗山路21号会议室以现场与通讯相结合方式召开。本次会议应参与表决董事7人，实际参 与表决董事7人，其中张平先生、黄鹏先生以通讯方式参与表决。公司高级管理人员列席会议，会议由 公司董事长李锂先生主持。本次会议的通知、召开以及参与表决董事人数均符合相关法律法规及《公司 章程》的有关规定。 二、董事会会议审议情况 经与会董事认真审议并通过了以下议案： 1、《关于取消监事会暨修订〈公司章程〉及相关治理制度的议案》 表决结果：7票同意、0票弃权、0票反对。 经审核，公司董事会同意对《公司章程》及相关治理制度进行修订，主要修订内容包括：根据《中华人 民共和国公司法》（ ...

证券日报网讯 11月24日晚间，海普瑞发布公告称，根据有关规定，独立董事在同一上市公司连续任职 时间不得超过六年。公司现任独立董事吕川先生连续任职时间即将届满六年。根据前述规定，届满离任 后，吕川先生将不再担任包括公司第六届董事会独立董事及董事会专门委员会相应职务（包括提名委员 会主任委员、审计委员会委员及战略委员会委员）在内的任何职务。2025年11月24日，公司召开第六届 董事会第十八次会议，会议审议通过了《关于独立董事任期届满离任暨补选独立董事的议案》，董事会 同意浦洪先生为公司第六届董事会独立董事候选人，若浦洪先生的独立董事任职获公司股东会审议通 过，其将同时担任董事会提名委员会主任委员、董事会审计委员会委员及董事会战略委员会委员职务， 任期自公司2025年第一次临时股东会审议通过之日起至第六届董事会任期届满之日止。 （文章来源：证券日报） ...

Core Points - The company, Haiprui (09989.HK), announced a decision by the board to propose the cancellation of the supervisory board and the positions of supervisors [1] - According to the provisions of the Company Law of China, the functions and responsibilities of the supervisory board will be assumed by the audit committee under the board [1] - The positions of the sixth supervisory board will be automatically terminated [1] - The proposal to cancel the supervisory board, amend the articles of association, and revise related systems must be approved by shareholders at a special resolution during a temporary shareholders' meeting for it to take effect [1]

海普瑞（002399）(09989)发布公告，董事会建议选举浦洪为独立非执行董事，惟须待股东于临时股东 大会上批准后方可作实。 ...

格隆汇11月24日丨海普瑞(09989.HK)公告，董事会决议建议取消监事会及公司监事职位。根据《中国公 司法》规定之监事会职权与职责应由董事会辖下之审计委员会行使。公司第六届监事会之监事职位将自 动解除。建议取消监事会、建议修订章程及建议修订相关制度须待公司股东于公司临时股东大会上以特 别决议案方式批准后，方告生效。 ...

代表委任表格 適用於二零二五年十二月十六日（星期二）舉行的 二零二五年第一次臨時股東大會 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） （附註7） ： 附註： 本人╱吾等 （附註1） 地址為 （附註2） 為深圳市海普瑞藥業集團股份有限公司（「貴公司」或「本公司」）股本中每股面值人民幣1.00元的H股 （附註3） 股的登記持有人，茲委任大會主席或 （全名） 地址為 （附註4及5） 為本人╱吾等的受委代表，代表本人╱吾等出席 貴公司於二零二五年十二月十六日（星期二）下午二時正（香 港時間）假座中國深圳市南山區南海大道3031號蘭赫美特酒店二樓宴會廳舉行之二零二五年第一次臨時股東 大會（「臨時股東大會」）（及其任何續會），以考慮並酌情通過本公司日期為二零二五年十一月二十五日的臨 時股東大會通函及通告（「通告」）中所載的決議案，並在大會及其任何續會上代表本人╱吾等投票及依照下 列指示就臨時股東大會通告所列決議案行使法律、法規及 貴公司章程賦予受委代表的一切權利， ...

智通财经APP讯，海普瑞(09989)发布公告，董事会建议选举浦洪为独立非执行董事，惟须待股东于临时 股东大会上批准后方可作实。 ...